Cancer Immunology Research · 2018 · 117 citations · 30 references
Life SciencesImmunologyOncologyCancer ImmunologyTumor ImmunologyTumor MicroenvironmentCancer ImmunotherapyNatural Killer Cell BiologyNatural Killer Cell FunctionRegulatory T CellsT Cell BiologyTumor-infiltrating LymphocytesNatural Killer Cell Inhibitory SignalingNatural Regulatory T CellsRegulatory T Cell RecruitmentTumor Microenvironment Effects
Abstract Natural killer (NK) cells are capable of fighting viral infections and cancer. However, these responses are inhibited by immune suppressor cells in the tumor microenvironment. Tumor progression promotes the recruitment and generation of intratumoral regulatory T cells (Treg), associated with a poor prognosis in cancer patients. Here, we show that canonical NK cells are highly susceptible to Treg-mediated suppression, in contrast to highly resistant CD57+ FcϵRγ−NKG2C+ adaptive (CD56+CD3−) NK cells that expand in cytomegalovirus exposed individuals. Specifically, Tregs suppressed canonical but not adaptive NK-cell proliferation, IFNγ production, degranulation, and cytotoxicity. Treg-mediated suppression was associated with canonical NK-cell downregulation of TIM3, a receptor that activates NK-cell IFNγ production upon ligand engagement, and upregulation of the NK-cell inhibitory receptors PD-1 and the IL1 receptor family member, IL1R8 (SIGIRR or TIR8). Treg production of the IL1R8 ligand, IL37, contributed to the phenotypic changes and diminished function in Treg-suppressed canonical NK cells. Blocking PD-1, IL1R8, or IL37 abrogated Treg suppression of canonical NK cells while maintaining NK-cell TIM3 expression. Our data uncover new mechanisms of Treg-mediated suppression of canonical NK cells and identify that adaptive NK cells are inherently resistant to Treg suppression. Strategies to enhance the frequency of adaptive NK cells in the tumor microenvironment or to blunt Treg suppression of canonical NK cells will enhance the efficacy of NK-cell cancer immunotherapy. Cancer Immunol Res; 6(7); 766–75. ©2018 AACR.
30
François Ghiringhelli, Cédric Menard, Magali Terme et al. · The Journal of Experimental Medicine · 2005 · 919 citations · Full text
Life Sciences, Immunology, Oncology +17
IL-37 is a fundamental inhibitor of innate immunity
Marcel F. Nold, Claudia A. Nold‐Petry, Jarod A. Zepp et al. · Nature Immunology · 2010 · 844 citations